Study of the anti-angiogenic response of HUVEC endothelial cells to the treatment with Paclitaxel anti-cancer agen

Abstract

Cancer treatment is one of the most important challenges for healthcare systems today. Among the new chemotherapy agents, the Taxane family has been identified as the most powerful agent in a wide range of activities. Unlike tumor cells, normal endothelial cells have high stability and low mutation rates. Therefore, targeting endothelial cells can be more useful and effective than tumor cells. Despite the emergence of anti-angiogenic or proliferative effects of taxanes on endothelial cells, there are limited studies on how this effect is molecular. In this study, we investigated the effect of Paclitaxel on the expression of miRNAs mir-21, mir-106b and mir-155 and the target gene HIF-1α. Materials and Methods: Chemotherapy drugs used to treat various cancers, including Paclitaxel, in addition to therapeutic effects on cancer cells, have side effects on other cells and tissues, including endothelial cells lining the walls of blood vessels in cancer tissue and other tissues. Are healthy, which have beneficial (inhibitory on tumor tissue) and harmful (inhibitory on other blood vessels) effects, respectively. HUVEC cell line is cultured in RPMI1640 medium and MTT assay is performed on them with different concentrations of Paclitaxel. The cells were then treated with IC50 drug concentration and total RNA was extracted and after cDNA synthesis, using real-time PCR quantification of mRNA and miRNAs controlling the expression of angiogenesis-related genes (mir-21, mir-106b and mir-155). And a target gene, HIGF-1α) will be examined. Results: Treatment of the target cells with paclitaxel caused changes in the expression of the studied genes, so that the expression of mir-155 and mir-106b genes decreased significantly and mir-21 significantly increased.